408356-52-5

Usage

Uses

Used in Organic Synthesis:
C-(1H-INDOL-7-YL)-METHYLAMINE is used as a precursor in organic synthesis for the creation of various indole-based compounds, which can have a range of applications in different fields due to their unique chemical properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, C-(1H-INDOL-7-YL)-METHYLAMINE is utilized as a building block for the development of new drugs. Its role in the synthesis of biologically active molecules makes it a valuable component in medicinal chemistry, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Intermediates:
As a chemical intermediate, C-(1H-INDOL-7-YL)-METHYLAMINE is employed in the production of other chemical compounds, contributing to the synthesis of a wide array of products across various chemical and industrial applications.

InChI:InChI=1/C9H10N2/c10-6-8-3-1-2-7-4-5-11-9(7)8/h1-5,11H,6,10H2

Upstream product

• 1074-88-0 1H-indole-7-carbaldehyde 
• 1108723-69-8 (Z)-1H-indole-7-carbaldehyde oxime 

Relevant academic research and scientific papers

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

Methods and compounds for treating proliferative diseases

The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.